MilliporeSigma
  • Home
  • Search Results
  • Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.

Bioorganic & medicinal chemistry letters (2004-10-16)
Christopher J Helal, Mark A Sanner, Christopher B Cooper, Thomas Gant, Mavis Adam, John C Lucas, Zhijun Kang, Stanley Kupchinsky, Michael K Ahlijanian, Bonnie Tate, Frank S Menniti, Kristin Kelly, Marcia Peterson
ABSTRACT

High-throughput screening with cyclin-dependent kinase 5 (cdk5)/p25 led to the discovery of N-(5-isopropyl-thiazol-2-yl)isobutyramide (1). This compound is an equipotent inhibitor of cdk5 and cyclin-dependent kinase 2 (cdk2)/cyclin E (IC(50)=ca. 320nM). Parallel and directed synthesis techniques were utilized to explore the SAR of this series. Up to 60-fold improvements in potency at cdk5 and 12-fold selectivity over cdk2 were achieved.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Aminothiazole, 97%